Evofem Biosciences earnings release, May 18, 2026

Evofem Biosciences, Inc. (EVFM) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Evofem

Reports First Quarter 2026 Financial Results and Provides Business Update — Advancing Strategy to Increase and Diversify Revenue through

Ex-U.S. Commercialization — SAN

DIEGO, CA, May 18, 2026 — Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026.

“Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan Africa.

We look forward to non-dilutive capital from each of these markets in 2026.”

Notable advances in 2026 to-date include:

First

Quarter Financial Results

For the three months ended March 31, 2026, net sales were $0.9 million, versus $0.8 million in the prior year period. The increase was primarily due to the higher WAC and more favorable gross-to-net ratio for both PHEXX and SOLOSEC and higher SOLOSEC ex-factory sales in the 2026 period, partially offset by lower ex-factory sales for PHEXX in the 2026 period following the exceptionally high level of PHEXX purchasing by wholesalers in December 2025 ahead of the January 2026 price increase.

Total operating expenses were $5.5 million in the first quarter of 2026, compared to $6.1 million in the prior year period, after excluding a one-time $5.6 million reduction in research and development expense as a result of its successful settlement of a portion of its trade payables with multiple vendors.

As a result, net loss was $5.5 million, or $(0.04) per basic and diluted share, in the first quarter of 2026.

This compares to net income attributable to common stockholders of $1.0 million, or $0.01 per basic and $0.00 per fully diluted share, in the first quarter of 2025.

About

Evofem

Evofem

Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products:

PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (In thousands, except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Product sales, net899845
Operating Expenses:Cost of goods sold410365
Operating Expenses:Amortization of intangible asset75223
Operating Expenses:Research and development, net518-5,035
Operating Expenses:Selling and marketing2,0932,600
Operating Expenses:General and administrative2,3722,365
Operating Expenses:Total operating expenses5,468518
Operating Expenses:Income (loss) from operations-4,569327
Other income (expense):Interest income28
Other income (expense):Other expense, net-737-600
Other income (expense):Change in fair value of financial instruments-1621,221
Other income (expense):Total other income (expense), net-897629
Other income (expense):Income (loss) before income tax expense-5,466956
Other income (expense):Income tax expense1
Other income (expense):Net income (loss)-5,465956
Other income (expense):Convertible and redeemable preferred stock deemed dividends-20-3
Other income (expense):Net income (loss) attributable to common stockholders-5,485953
Net income (loss) per share attributable to common stockholders:Basic-0.040.01
Net income (loss) per share attributable to common stockholders:Diluted-0.040
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:Basic133,246,864118,164,046
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:Diluted133,246,8646,155,035,291

Balance Sheet

(unaudited) (In thousands) (in thousands)

As of – March 31, 2026As of – December 31, 2025
Cash and cash equivalents1,491$-
Restricted cash and cash equivalents888578
Trade accounts receivable, net56012,480
Total current liabilities78,75284,820
Total stockholders’ deficit-77,630-74,336
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit7,44220,274
Full release

This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.

Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,”

“hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to, Evofem’s expectations regarding the anticipated impact of COGS reduction initiatives, the commercialization of PHEXX and SOLOSEC, the timing and outcome of the EDE review of the submissions for PHEXX and SOLOSEC in the UAE, and the timing and magnitude of anticipated future commercial orders for and product launches in ex-U.S. markets. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, the nonrecurring nature of certain recent gains, risks related to the Company’s limited revenue base relative to operating expenses, and its reliance on third-party licensees and distributors for ex-U.S. commercialization, together with those that are disclosed in the Company’s SEC filings, including its

Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 11, 2026, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 15, 2026, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business conditions.

Sources

Connect with Us ir@evofem.com media@evofem.com

Financial

Tables Follow

EVOFEM

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Evofem Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.